Nasr Michael, Sigdel Tara, Sarwal Minnie
a Sarwal Lab , University of California, San Francisco , San Francisco , CA , USA.
b Department of Bioengineering & Therapeutic Sciences , University of California, San Francisco , San Francisco , CA , USA.
Expert Rev Mol Diagn. 2016 Oct;16(10):1121-1132. doi: 10.1080/14737159.2016.1239530.
Identification of allograft injury, including acute clinical and subclinical injury, is vital in increasing the longevity of the transplanted organ. Acute rejection, which occurs as a result of a variety of immune and non-immune factors including the infiltration of immune cells and antibodies to the donor specific epitopes, poses a significant risk to the organ. Recent years have marked an increase in the discovery of new genomic, transcriptomic, and proteomic biomarkers in molecular diagnostics, which offer better potential for personalized management of the transplanted organ by providing earlier detection of rejection episodes. Areas covered: This review was compiled from key word searches of full-text publications relevant to the field. Expert commentary: Many of the recent advancements in the molecular diagnostics of allograft injury show much promise, but before they can be fully realized further validation in larger sample sets must be conducted. Additionally, for better informed therapeutic decisions, more work must be completed to differentiate between different causes of injury. Moreover, the diagnostics field is looking at methodologies that allow for multiplexing, the ability to identify multiple targets simultaneously, in order to provide more robust biomarkers and better understanding.
识别同种异体移植损伤，包括急性临床损伤和亚临床损伤，对于延长移植器官的寿命至关重要。急性排斥反应是由多种免疫和非免疫因素引起的，包括免疫细胞浸润和针对供体特异性表位的抗体，对器官构成重大风险。近年来，分子诊断中新型基因组、转录组和蛋白质组生物标志物的发现有所增加，通过更早地检测排斥反应，为移植器官的个性化管理提供了更好的潜力。涵盖领域：本综述是通过对该领域相关全文出版物进行关键词搜索汇编而成。专家评论：同种异体移植损伤分子诊断的许多最新进展显示出很大的前景，但在它们能够完全实现之前，必须在更大的样本集中进行进一步验证。此外，为了做出更明智的治疗决策，必须完成更多工作以区分不同的损伤原因。此外，诊断领域正在研究允许多重检测的方法，即同时识别多个靶点的能力，以便提供更可靠的生物标志物并增进理解。
